← All trials
NCT05106946
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 25, 2021
- Primary completion
- Oct 25, 2023
- Completion date
- Oct 25, 2024
- First posted
- Nov 4, 2021
- Last posted
- Nov 11, 2021
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fundamenta Therapeutics, Ltd.Lead sponsor
- Xuzhou Medical UniversityStudy chair
- Xuzhou Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.